BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
February 08, 2024 05:45 ET
|
Autolus Therapeutics plc; BioNTech SE
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
January 22, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces acceptance of BLA for obe-cel as a potential treatment for relapsed/refractory adult ALL
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
January 10, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
Autolus Therapeutics Announces Changes to its Board of Directors
December 22, 2023 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Announces Changes to its Board of Directors
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
December 09, 2023 20:30 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
November 27, 2023 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel)
Autolus Therapeutics announces participation in upcoming conferences
November 06, 2023 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces participation in upcoming conferences
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations
November 02, 2023 09:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
November 02, 2023 07:11 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress
August 03, 2023 07:00 ET
|
Autolus Therapeutics plc
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US...